For Sangamo Therapeutics, science is a means to develop new medicines to transform the lives of patients living with serious genetic diseases.
With 21 years of experience, Sangamo is a pioneer in research and development of new gene-based therapies.
We seek to gain perspectives from patients, caregivers and their advocates in order to understand the daily challenges of those we are here to serve.
Industry leading technologies in gene therapy, genome editing, cell therapy and gene regulation
News + Events
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences
Sangamo Therapeutics Announces Presentation At The 2018 Wedbush PacGrow Healthcare Conference